- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Intensive care medicine. - 50, 6 (2024) , 1010-1012, ISSN: 1432-1238
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2024
- DOI
-
10.1007/s00134-024-07432-5
- URN
-
urn:nbn:de:bsz:25-freidok-2469230
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:45 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Entstanden
- 2024
Ähnliche Objekte (12)
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Correction: Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP) - a single center, open-label, three-arm, randomized, controlled intervention trial
Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)—a single center, open-label, three-arm, randomized, controlled intervention trial
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP) — Aasingle center, open‐label, three‐arm, randomized, controlled intervention pilot trial
"A wolf in sheep's clothing"
The wolf in sheep's clothing
"A wolf in sheep's clothing"
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Klinisches Vorgehen bei Leberabszessen
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Correction: Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP) - a single center, open-label, three-arm, randomized, controlled intervention trial
Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)—a single center, open-label, three-arm, randomized, controlled intervention trial
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP) — Aasingle center, open‐label, three‐arm, randomized, controlled intervention pilot trial
"A wolf in sheep's clothing"
The wolf in sheep's clothing
"A wolf in sheep's clothing"
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Klinisches Vorgehen bei Leberabszessen
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Zellzyklus regulierende Funktion der Mammalian-STE20-like-Kinase-1 (MST1)
Correction: Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP) - a single center, open-label, three-arm, randomized, controlled intervention trial
Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)—a single center, open-label, three-arm, randomized, controlled intervention trial
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP) — Aasingle center, open‐label, three‐arm, randomized, controlled intervention pilot trial
"A wolf in sheep's clothing"
The wolf in sheep's clothing
"A wolf in sheep's clothing"
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab